Immuron Ltd. Describes How their Gastrointestinal and Digestive Health Immune Supplements Work + FY23 Sales Announcement in New CEO Video Interview on Planet MicroCap

LOS ANGELES, CA / ACCESSWIRE / July 19, 2023 / Planet MicroCap today published a new Video Interview with Steven Lydeamore, CEO of Immuron Ltd. (ASX:IMC)(NASDAQ:IMRN). Immuron Limited (ASX:IMC, NASDAQ:IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, according to the company's website (see here: http://www.immuron.com).

Click the following link to watch the Video Interview:

Immuron on How their Gastrointestinal and Digestive Health Immune Supplements Work + FY23 Sales

You can follow Planet MicroCap on TWITTER, LINKEDIN, YOUTUBE

Please review important disclosures on our website at: https://snn.network/terms-of-use

About Immuron

Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.

For more information visit: http://www.immuron.com

About Planet MicroCap

Planet MicroCap is a global multimedia financial news, publishing and events company focused on news dissemination, providing information, data and analytics for the MicroCap investing community. We have cultivated an active and engaged audience of folks that are interested in learning about and to stay ahead of the curve in the MicroCap space. You can subscribe to Planet MicroCap's YouTube Channel here: https://www.youtube.com/snnwire

CONTACT:

Planet MicroCap
info@snnwire.com

SOURCE: Planet MicroCap Review Magazine